Long-term Kidney Transplant Survival Across the Globe.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
medline:
19
3
2024
pubmed:
19
3
2024
entrez:
19
3
2024
Statut:
aheadofprint
Résumé
The outcomes after kidney transplantation (KT), including access, wait time, and other issues around the globe, have been studied. However, issues do vary from one country to another. We obtained data from several countries from North America, South America, Europe, Asia, and Australia, including the number of patients awaiting KT from 2015, transplant rate per million population (pmp), proportion of living donor and deceased donor (LD/DD) KT, and posttransplant survival. We also sought opinions on key difficulties faced by each of these countries with respect to KT and long-term survival. Variation in access to KT across the globe was noted. Countries with the highest rates of KT pmp included the United States (79%) and Spain (71%). A higher proportion of LD transplants was noted in Japan (93%), India (85%), Singapore (63%), and South Korea (63%). A higher proportion of DD KTs was noted in Spain (90%), Brazil (90%), France (85%), Italy (85%), Finland (85%), Australia-New Zealand (80%), and the United States (77%). The 5-y graft survival for LD was highest in South Korea (95%), Singapore (94%), Italy (93%), Finland (93%), and Japan (93%), whereas for DD, it was South Korea (93%), Italy (88%), Japan (86%), and Singapore (86%). The common issues surrounding KTs are access and a limited number of LDs and DDs. Key issues identified for long-term survival were increasing age of donors and recipients, higher recipient comorbidity, and posttransplant events, such as alloimmune injury to the kidney, infection, cancer, and suboptimal adherence to therapy. A unified approach is necessary to improve issues surrounding KT as the demand continues to increase.
Sections du résumé
BACKGROUND
BACKGROUND
The outcomes after kidney transplantation (KT), including access, wait time, and other issues around the globe, have been studied. However, issues do vary from one country to another.
METHODS
METHODS
We obtained data from several countries from North America, South America, Europe, Asia, and Australia, including the number of patients awaiting KT from 2015, transplant rate per million population (pmp), proportion of living donor and deceased donor (LD/DD) KT, and posttransplant survival. We also sought opinions on key difficulties faced by each of these countries with respect to KT and long-term survival.
RESULTS
RESULTS
Variation in access to KT across the globe was noted. Countries with the highest rates of KT pmp included the United States (79%) and Spain (71%). A higher proportion of LD transplants was noted in Japan (93%), India (85%), Singapore (63%), and South Korea (63%). A higher proportion of DD KTs was noted in Spain (90%), Brazil (90%), France (85%), Italy (85%), Finland (85%), Australia-New Zealand (80%), and the United States (77%). The 5-y graft survival for LD was highest in South Korea (95%), Singapore (94%), Italy (93%), Finland (93%), and Japan (93%), whereas for DD, it was South Korea (93%), Italy (88%), Japan (86%), and Singapore (86%). The common issues surrounding KTs are access and a limited number of LDs and DDs. Key issues identified for long-term survival were increasing age of donors and recipients, higher recipient comorbidity, and posttransplant events, such as alloimmune injury to the kidney, infection, cancer, and suboptimal adherence to therapy.
CONCLUSIONS
CONCLUSIONS
A unified approach is necessary to improve issues surrounding KT as the demand continues to increase.
Identifiants
pubmed: 38499511
doi: 10.1097/TP.0000000000004977
pii: 00007890-990000000-00694
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Hariharan S, Israni AK, Danovitch G. Long-term survival after kidney transplantation. N Engl J Med. 2021;385:729–743.
Collaboration GBDCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–733.
Bello AK, Levin A, Lunney M, et al. Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ. 2019;367:l5873.
Divard G, Goutaudier V. Global perspective on kidney transplantation: France. Kidney360. 2021;2:1637–1640.
Kute VB, Ramesh V, Rela M. On the way to self-sufficiency: improving deceased organ donation in India. Transplantation. 2021;105:1625–1630.
Kute VB, Meshram HS, Mahillo B, et al. Current status, challenges, and opportunities of organ donation and transplantation in India. Transplantation. 2023;107:1213–1218.
Kute VB, Vanikar AV, Patel HV, et al. Outcome of renal transplantation from deceased donors: experience from developing country. Ren Fail. 2014;36:1215–1220.
Mehta RB, Melgarejo I, Viswanathan V, et al. Long-term immunological outcomes of early subclinical inflammation on surveillance kidney allograft biopsies. Kidney Int. 2022;102:1371–1381.
Rampersad C, Balshaw R, Gibson IW, et al. The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. Am J Transplant. 2022;22:761–771.
Remuzzi G, Cravedi P, Perna A, et al.; Dual Kidney Transplant Group. Long-term outcome of renal transplantation from older donors. N Engl J Med. 2006;354:343–352.
Hart A, Gustafson SK, Wey A, et al. The association between loss of Medicare, immunosuppressive medication use, and kidney transplant outcomes. Am J Transplant. 2019;19:1964–1971.
McKinney WT, Schladt D, Miller J, et al. Racial barriers to kidney transplant after listing, 2015–2020 [abstract]. Am J Transplant. 2022;22 (suppl 3). Available at https://atcmeetingabstracts.com/abstract/racial-barriers-to-kidney-transplant-after-listing-2015-2020/. Accessed March 3, 2024.
Doberer K, Duerr M, Halloran PF, et al. A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol. 2021;32:708–722.
El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527–535.
Sharma A, Cherukuri A, Mehta RB, et al. High calcineurin inhibitor intrapatient variability is associated with renal allograft inflammation, chronicity, and graft loss. Transplant Direct. 2019;5:e424.
Snyder JJ, Israni AK, Peng Y, et al. Rates of first infection following kidney transplant in the United States. Kidney Int. 2009;75:317–326.
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–1901.